Clinical trials enable breakthrough treatment of IBS 

Enbiosis has made breakthrough in the treatment of irritable bowel syndrome (IBS), with 78% of the IBS patients who followed microbiome-based diets seeing symptoms improve dramatically.  

Dr. Tarkan Karakan, a gastroenterology specialist who helped conduct the study, said: “We believe this achievement represents a significant step towards demonstrating the efficacy of personalised medical solutions. We examined intestinal flora of IBS sufferers before prescribing dietary regimes based on the findings. This novel approach to IBS treatment is the first time for microbiome modulation to be used to alleviate symptoms of gastrointestinal disorders.” 

Enbiosis has also developed prebiotic prescriptions for IBS sufferers. “Not to be confused with probiotics, prebiotics are non-digestible compounds that aid the development of beneficial gut bacteria,” Özkan Ufuk Nalbantoğlu, Chief Technology Officer of ENBIOSIS, explained. “So along with providing dietary strategies based on sound nutrition, we also help IBS patients fortify their gut flora – thus easing their symptoms – through the judicious use of prebiotics.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free